Skip to content

Thursday, September 28, 2023

Latest:

PARMESAN: An AI-based predictive tool to find new treatments for genetic disorders
What is a superfood?
Aortic dissection awareness saves lives: Understanding symptoms, causes, treatment options
Researchers combat Zika-associated fetal abnormalities using microRNA
Do medical schools provide adequate mental health care coverage for their students?

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

CDK4/6 inhibitor therapy

Interferon linked to ER+/HER- metastatic breast cancer resistance to therapy

March 12, 2021March 12, 2021 CDK4/6 inhibitor therapy, endocrine therapy, ER+/HER2- breast cancer, Interferon, Metastatic breast cancer, Research, resistance to cancr treatment

Both preclinical models and tumor samples from patients with ER+/HER2- breast cancer link high IFN signaling to resistance to treatment.

From the Labs Image of the Month

From the Labs: Plasticity of adult-born neurons.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951